Literature DB >> 15361068

Characterization of the survival motor neuron (SMN) promoter provides evidence for complex combinatorial regulation in undifferentiated and differentiated P19 cells.

Raphaël Rouget1, François Vigneault, Circé Codio, Camille Rochette, Isabelle Paradis, Régen Drouin, Louise R Simard.   

Abstract

There exist two SMN (survival motor neuron) genes in humans, the result of a 500 kb duplication in chromosome 5q13. Deletions/mutations in the SMN1 gene are responsible for childhood spinal muscular atrophy, an autosomal recessive neurodegenerative disorder. While the SMN1 and SMN2 genes are not functionally equivalent, up-regulation of the SMN2 gene represents an important therapeutic target. Consequently, we exploited in silico, in vitro and in vivo approaches to characterize the core human and mouse promoters in undifferentiated and differentiated P19 cells. Phylogenetic comparison revealed four highly conserved regions that contained a number of cis-elements, only some of which were shown to activate/repress SMN promoter activity. Interestingly, the effect of two Sp1 cis-elements varied depending on the state of P19 cells and was only observed in combination with a neighbouring Ets cis-element. Electrophoretic mobility-shift assay and in vivo DNA footprinting provided evidence for DNA-protein interactions involving Sp, NF-IL6 and Ets cis-elements, whereas transient transfection experiments revealed complex interactions involving these recognition sites. SMN promoter activity was strongly regulated by an NF-IL6 response element and this regulation was potentiated by a downstream Ets element. In vivo results suggested that the NF-IL6 response must function either via a protein-tethered transactivation mechanism or a transcription factor binding an upstream element. Our results provide strong evidence for complex combinatorial regulation and suggest that the composition or state of the basal transcription complex binding to the SMN promoter is different between undifferentiated and differentiated P19 cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15361068      PMCID: PMC1134714          DOI: 10.1042/BJ20041024

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  50 in total

1.  Transactivation via RAR/RXR-Sp1 interaction: characterization of binding between Sp1 and GC box motif.

Authors:  J Shimada; Y Suzuki; S J Kim; P C Wang; M Matsumura; S Kojima
Journal:  Mol Endocrinol       Date:  2001-10

2.  Nuclear factor 1 interferes with Sp1 binding through a composite element on the rat poly(ADP-ribose) polymerase promoter to modulate its activity in vitro.

Authors:  M A Laniel; G G Poirier; S L Guerin
Journal:  J Biol Chem       Date:  2001-03-07       Impact factor: 5.157

3.  A vision for the future of genomics research.

Authors:  Francis S Collins; Eric D Green; Alan E Guttmacher; Mark S Guyer
Journal:  Nature       Date:  2003-04-14       Impact factor: 49.962

Review 4.  The SMN complex.

Authors:  Amelie K Gubitz; Wenqin Feng; Gideon Dreyfuss
Journal:  Exp Cell Res       Date:  2004-05-15       Impact factor: 3.905

5.  Molecular cloning and characterization of PEA3, a new member of the Ets oncogene family that is differentially expressed in mouse embryonic cells.

Authors:  J H Xin; A Cowie; P Lachance; J A Hassell
Journal:  Genes Dev       Date:  1992-03       Impact factor: 11.361

6.  Characterization of a retinoic acid responsive element in the human ets-1 promoter.

Authors:  E N So; D L Crowe
Journal:  IUBMB Life       Date:  2000-12       Impact factor: 3.885

Review 7.  An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA).

Authors:  B Wirth
Journal:  Hum Mutat       Date:  2000       Impact factor: 4.878

8.  Binding of transcription factors creates hot spots for UV photoproducts in vivo.

Authors:  G P Pfeifer; R Drouin; A D Riggs; G P Holmquist
Journal:  Mol Cell Biol       Date:  1992-04       Impact factor: 4.272

9.  Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6.

Authors:  I L Campbell; C R Abraham; E Masliah; P Kemper; J D Inglis; M B Oldstone; L Mucke
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-01       Impact factor: 11.205

10.  cDNA cloning of human N-Oct3, a nervous-system specific POU domain transcription factor binding to the octamer DNA motif.

Authors:  E Schreiber; A Tobler; U Malipiero; W Schaffner; A Fontana
Journal:  Nucleic Acids Res       Date:  1993-01-25       Impact factor: 16.971

View more
  9 in total

1.  Effects of 2,4-diaminoquinazoline derivatives on SMN expression and phenotype in a mouse model for spinal muscular atrophy.

Authors:  Matthew E R Butchbach; Jasbir Singh; Margrét Thorsteinsdóttir; Luciano Saieva; Elzbieta Slominski; John Thurmond; Thorkell Andrésson; Jun Zhang; Jonathan D Edwards; Louise R Simard; Livio Pellizzoni; Jill Jarecki; Arthur H M Burghes; Mark E Gurney
Journal:  Hum Mol Genet       Date:  2009-11-06       Impact factor: 6.150

Review 2.  Therapeutics development for spinal muscular atrophy.

Authors:  Charlotte J Sumner
Journal:  NeuroRx       Date:  2006-04

3.  Age-dependent SMN expression in disease-relevant tissue and implications for SMA treatment.

Authors:  Daniel M Ramos; Constantin d'Ydewalle; Vijayalakshmi Gabbeta; Amal Dakka; Stephanie K Klein; Daniel A Norris; John Matson; Shannon J Taylor; Phillip G Zaworski; Thomas W Prior; Pamela J Snyder; David Valdivia; Christine L Hatem; Ian Waters; Nikhil Gupte; Kathryn J Swoboda; Frank Rigo; C Frank Bennett; Nikolai Naryshkin; Sergey Paushkin; Thomas O Crawford; Charlotte J Sumner
Journal:  J Clin Invest       Date:  2019-11-01       Impact factor: 14.808

4.  Transcriptional regulation of the cyclin-dependent kinase inhibitor 1A (p21) gene by NFI in proliferating human cells.

Authors:  Stéphane Ouellet; François Vigneault; Maryse Lessard; Steeve Leclerc; Régen Drouin; Sylvain L Guérin
Journal:  Nucleic Acids Res       Date:  2006-11-27       Impact factor: 16.971

Review 5.  Therapy development for spinal muscular atrophy: perspectives for muscular dystrophies and neurodegenerative disorders.

Authors:  Sibylle Jablonka; Luisa Hennlein; Michael Sendtner
Journal:  Neurol Res Pract       Date:  2022-01-04

6.  Survival motor neuron gene 2 silencing by DNA methylation correlates with spinal muscular atrophy disease severity and can be bypassed by histone deacetylase inhibition.

Authors:  Jan Hauke; Markus Riessland; Sebastian Lunke; Ilker Y Eyüpoglu; Ingmar Blümcke; Assam El-Osta; Brunhilde Wirth; Eric Hahnen
Journal:  Hum Mol Genet       Date:  2008-10-29       Impact factor: 6.150

7.  Oxidative Stress Triggers Body-Wide Skipping of Multiple Exons of the Spinal Muscular Atrophy Gene.

Authors:  Joonbae Seo; Natalia N Singh; Eric W Ottesen; Senthilkumar Sivanesan; Maria Shishimorova; Ravindra N Singh
Journal:  PLoS One       Date:  2016-04-25       Impact factor: 3.240

8.  Severe impairment of male reproductive organ development in a low SMN expressing mouse model of spinal muscular atrophy.

Authors:  Eric W Ottesen; Matthew D Howell; Natalia N Singh; Joonbae Seo; Elizabeth M Whitley; Ravindra N Singh
Journal:  Sci Rep       Date:  2016-02-02       Impact factor: 4.379

9.  A high-throughput genome-wide RNAi screen identifies modifiers of survival motor neuron protein.

Authors:  Nikki M McCormack; Mahlet B Abera; Eveline S Arnold; Rebecca M Gibbs; Scott E Martin; Eugen Buehler; Yu-Chi Chen; Lu Chen; Kenneth H Fischbeck; Barrington G Burnett
Journal:  Cell Rep       Date:  2021-05-11       Impact factor: 9.423

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.